Changing the way women are treated for breast cancer could improve their overall chance of survival, according to research published today in the Lancet. The new paper shows that switching to a drug called exemestane, two to three years after commencing standard therapy with the drug tamoxifen, can cut the risk of death for certain women by a further 17 percent compared with using tamoxifen alone.
A large animal study has shown that certain microsecond electrical pulses can punch nanoscale holes in the membranes of target cells without harming tissue scaffolding, including that in the blood vessels – a potential breakthrough in minimally invasive surgical treatments of tumors.
In a new report in the February 15th issue of G&D, Dr. Martin McMahon (UCSF) and colleagues present a novel mouse model of non-small cell lung cancer, which will serve as a useful tool to test the efficacy of novel chemotherapeutic drug therapies in the early stages of lung tumorigenesis.
A new study finds that p38-alpha MAPK can sense oxidative stress in cells and respond by inhibiting tumor formation. The research, published in the February issue of the journal Cancer Cell, published by Cell Press, provides exciting new insight into the specific mechanisms by which ? suppresses the development of cancer and identifies possible targets for development of new anticancer therapeutics.
Nearly 20 percent of women who develop lung cancer have never smoked, US researchers found in a study that suggests secondhand smoke may be to blame.
For breast cancer patients taking tamoxifen, switching to an aromatase inhibitor within three years significantly improves survival rates, according to a new study.
Aggressive research currently underway brings hope of dramatic advances in breast cancer management, according to a new review.
Proacta Therapeutics, a spin-out company of The University of Auckland, has raised US$35 million (NZ$51 million) in venture capital to continue its research into potential treatments for cancer.
A study led by researchers at Dana-Farber Cancer Institute and Broad Institute of the Massachusetts Institute of Technology and Harvard University provides the first demonstration of a practical method of screening tumors for cancer-related gene abnormalities that might be treated with “targeted” drugs.
Two mutations in the gene for a rare genetic disorder appear to be associated with an increased risk of breast cancer, a new study suggests.